Загрузка...
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
BACKGROUND AND AIMS: First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype 1 infection in most countries for 3 years. We have investigated the efficacy and tolerance of this triple therapy...
Сохранить в:
Опубликовано в: : | PLoS One |
---|---|
Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
Public Library of Science
2015
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4578772/ https://ncbi.nlm.nih.gov/pubmed/26394142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0138091 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|